UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S96-S96

2017

Volltextzugriff (PDF)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation

Issledovaniâ i praktika v medicine, 2023-03, Vol.10 (1), p.27-35

2023

Volltextzugriff (PDF)

Alteration of red blood cell microrheology by anti-tumor chemotherapy drugs

Biochemistry (Moscow). Supplement series A, Membrane and cell biology, 2016-04, Vol.10 (2), p.135-141

2016

Volltextzugriff (PDF)

Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients

Clinical hemorheology and microcirculation, 2010, Vol.44 (2), p.115-123

2010

Volltextzugriff (PDF)

Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)

Annals of oncology, 2016-10, Vol.27, p.vi123-vi123

2016

Volltextzugriff (PDF)

Pharmacotherapy regimens for patients with hormone-receptor positive (HR+), human epidermal growth factor 2 negative (HER2–) metastatic breast cancer in routine clinical practice (results of non-interventional retrospective study)

Medical alphabet, 2023-01 (31), p.7-14

2023

Volltextzugriff (PDF)

713 - Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S96-S96

2017

Volltextzugriff (PDF)

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

European journal of cancer supplements, 2008, Vol.6 (7), p.172-172

2008

Volltextzugriff (PDF)

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.215-215

2007

Volltextzugriff (PDF)

Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

Annals of oncology, 2016-10, Vol.27, p.vi285-vi285

2016

Volltextzugriff (PDF)

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.376-377

2007

Volltextzugriff (PDF)

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-19-13

2011

Volltextzugriff (PDF)

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-19-03

2011

Volltextzugriff (PDF)

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.275-275

2011

Volltextzugriff (PDF)

The choice of treatment for chemorefractory colon cancer

Malignant tumours, 2023-11, Vol.13 (3), p.56-63

2023

Volltextzugriff (PDF)

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4026-4026

2009

Volltextzugriff (PDF)

Abstract P6-11-02: Final Analysis of NO16853, a Randomized Phase II Non-Inferiority Study of Two Different Doses of Capecitabine in Combination with Docetaxel for Locally Advanced/Metastatic Breast Cancer (LA/MBC)

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P6-P6-11-02

2010

Volltextzugriff (PDF)

Изменение микрореологических свойств эритроцитов под действием препаратов химиотерапии опухолей

Биологические мембраны: Журнал мембранной и клеточной биологии, 2016, Vol.33 (1), p.62-69

2016

Volltextzugriff (PDF)

Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1082-1082

2008

Volltextzugriff (PDF)

First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4100-4100

2008

Volltextzugriff (PDF)

Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.1032-1032

2007

Volltextzugriff (PDF)

Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.7659-7659

2007

Volltextzugriff (PDF)

A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (HRPC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5153-5153

2008

Volltextzugriff (PDF)

Dose escalation study of nab- paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7132-7132

2006

Volltextzugriff (PDF)

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Annals of oncology, 2012-03, Vol.23 (3), p.589

2012

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(37)
magazinearticle
(10)

Sprache

Englisch
(45)
Russisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

Systemic therapy of skin metastatic melanoma with BRAF gene mutation

Alteration of red blood cell microrheology by anti-tumor chemotherapy drugs

Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients

Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)

Pharmacotherapy regimens for patients with hormone-receptor positive (HR+), human epidermal growth factor 2 negative (HER2–) metastatic breast cancer in routine clinical practice (results of non-interventional retrospective study)

713 - Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

The choice of treatment for chemorefractory colon cancer

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)

Abstract P6-11-02: Final Analysis of NO16853, a Randomized Phase II Non-Inferiority Study of Two Different Doses of Capecitabine in Combination with Docetaxel for Locally Advanced/Metastatic Breast Cancer (LA/MBC)

Изменение микрореологических свойств эритроцитов под действием препаратов химиотерапии опухолей

Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC)

First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC)

Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)

A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (HRPC)

Dose escalation study of nab- paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC)

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Aktive Filter

Suchergebnisse filtern